Medivir to present at Swiss Nordic Bio in Zürich on March 7

Rhea-AI Summary

Medivir AB (MVIR) to present at Swiss Nordic Bio conference, focusing on fostrox clinical study data for cancer treatment acceleration.

STOCKHOLM, March 6, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Swiss Nordic Bio conference on March 7, 2024.

CEO Jens Lindberg will present Medivir with focus on data from the ongoing phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) and how these data enable an acceleration of fostrox's development program.

Swiss Nordic Bio aims to bring together biotech, pharma and life science investors from Switzerland and the Nordic region. In addition to the presentation, the company will also conduct a number of 1-1 meetings with potential investors and partners.

After the meeting, the presentation will also be available on Medivir's website www.medivir.se.

For additional information, please contact
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com 

Medivir in brief

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com. 

The following files are available for download:

https://mb.cision.com/Main/652/3941422/2650494.pdf

Press release (PDF)

 

View original content:https://www.prnewswire.com/news-releases/medivir-to-present-at-swiss-nordic-bio-in-zurich-on-march-7-302081092.html

SOURCE Medivir

FAQ

What is the ticker symbol for Medivir AB?

The ticker symbol for Medivir AB is MVIR.

What is the focus of Medivir AB's presentation at the Swiss Nordic Bio conference?

Medivir AB will focus on data from the ongoing phase 1b/2a clinical study with fostrox for cancer treatment acceleration.

Who will present Medivir AB at the Swiss Nordic Bio conference?

CEO Jens Lindberg will present Medivir AB at the Swiss Nordic Bio conference.

What is the purpose of Swiss Nordic Bio conference?

Swiss Nordic Bio conference aims to bring together biotech, pharma, and life science investors from Switzerland and the Nordic region.

Where can the presentation be found after the conference?

The presentation will be available on Medivir's website www.medivir.se after the conference.